Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2011

View Archived Issues

Korean scientists synthesize novel protein kinase inhibitors

Phase II trial of antisense drug iCo-007 begins in the U.S.

Public gene expression data used to reposition drugs for new indications

SRT-1720 has beneficial effects in obesity model

New genetic variants in multiple sclerosis identified

Advinus Therapeutics discloses novel glucokinase activators

New immunosuppressants disclosed by Daiichi Sankyo

Chinese researchers patent novel anticancer agents

Pfizer synthesizes novel tyrosine-protein kinase inhibitors

Australian research team patents novel agents for RSV infection

Vertex designs novel series of protein kinase inhibitors

Fresolimumab receives orphan drug designation in the E.U.

Delcath reports data from phase II trial of its chemosaturation system

Isconova announces expansion of vaccine collaboration with Genocea

Cell Therapeutics submits response to questions raised by EMA regarding pixantrone MAA

Mesoblast performs first lumbar disc procedure in phase II stem cell trial

Incivek obtains approval in Canada for hepatitis C

Mayo Clinic obtains IND clearance for ovarian and breast cancer vaccine trials

First patient enrolled in phase I/II study of Hemispherx's Ampligen in breast cancer

Symphogen begins phase II trial of Sym-004 in head and neck cancer

AstraZeneca launches Brilinta in the U.S. for patients with ACS

Bayer gains FDA fast track designation for Alpharadin

Nippon Kayaku files for approval of additional dosages and indications for Randa and Lastet in Japan

BioDelivery Sciences plans commercial launch of Onsolis in Canada

Cres Pharmaceuticals compound obtains orphan status for primary myelofibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...